398 related articles for article (PubMed ID: 24566187)
1. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
Zavascki AP; Nation RL
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
[TBL] [Abstract][Full Text] [Related]
3. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury.
Sisay M; Hagos B; Edessa D; Tadiwos Y; Mekuria AN
Pharmacol Res; 2021 Jan; 163():105328. PubMed ID: 33276108
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
[TBL] [Abstract][Full Text] [Related]
6. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin.
Ballı FN; Ekinci PB; Kurtaran M; Kara E; Dizman GT; Sönmezer MÇ; Hayran M; Demirkan K; Metan G
Int J Antimicrob Agents; 2024 Feb; 63(2):107035. PubMed ID: 37979889
[TBL] [Abstract][Full Text] [Related]
7. Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.
Pike M; Saltiel E
J Pharm Pract; 2014 Dec; 27(6):554-61. PubMed ID: 25237156
[TBL] [Abstract][Full Text] [Related]
8. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study.
Aggarwal R; Dewan A
Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):15. PubMed ID: 29571295
[TBL] [Abstract][Full Text] [Related]
9. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
Vardakas KZ; Falagas ME
Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.
Hassan MM; Gaifer Z; Al-Zakwani IS
Int J Clin Pharm; 2018 Apr; 40(2):444-449. PubMed ID: 29542034
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
[TBL] [Abstract][Full Text] [Related]
12. Imaging the distribution of polymyxins in the kidney.
Yun B; Azad MA; Wang J; Nation RL; Thompson PE; Roberts KD; Velkov T; Li J
J Antimicrob Chemother; 2015 Mar; 70(3):827-9. PubMed ID: 25377569
[TBL] [Abstract][Full Text] [Related]
13. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
[TBL] [Abstract][Full Text] [Related]
14. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?
Pogue JM; Ortwine JK; Kaye KS
Int J Antimicrob Agents; 2016 Dec; 48(6):622-626. PubMed ID: 27876274
[TBL] [Abstract][Full Text] [Related]
15. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.
Phe K; Shields RK; Tverdek FP; Aitken SL; Guervil DJ; Lam WM; Musgrove RJ; Luce AM; Tam VH
J Antimicrob Chemother; 2016 Dec; 71(12):3585-3587. PubMed ID: 27543655
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
[TBL] [Abstract][Full Text] [Related]
17. The safety of polymyxin antibiotics.
Kelesidis T; Falagas ME
Expert Opin Drug Saf; 2015; 14(11):1687-701. PubMed ID: 26365594
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
Hartzell JD; Neff R; Ake J; Howard R; Olson S; Paolino K; Vishnepolsky M; Weintrob A; Wortmann G
Clin Infect Dis; 2009 Jun; 48(12):1724-8. PubMed ID: 19438394
[TBL] [Abstract][Full Text] [Related]
20. Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections.
Simon V; Viswam A; Alexander PS; James E; Sudhindran S
Indian J Pharmacol; 2023; 55(4):229-236. PubMed ID: 37737075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
